Literature summary extracted from

Cory, J.G.; Sato, A.; Lasater, L.
Specific inhibition of the subunits of ribonucleotide reductase as a new approach to combination chemotherapy (1981), Adv. Enzyme Regul., 19, 139-150.

Inhibitors

EC Number	Inhibitors	Comment	Organism	Structure
1.17.4.1	1-Formylisoquinoline thiosemicarbazone	0.0006 mM, 81% inhibition, 0.1 mM desferal reverses inhibition	Mus musculus
1.17.4.1	2,3-Dihydro-1H-pyrazolo[2,3-a]imidazole	-	Mus musculus
1.17.4.1	3,5-diamino-1H-1,2,4-triazole	2 mM, 41% inhibition, presence of 0.1 mM desferal potentiates inhibition; trivial name guanazole	Mus musculus
1.17.4.1	4-Methyl-5-amino-1-formylisoquinoline thiosemicarbazone	0.0003 mM, 93% inhibition, 0.1 mM desferal reverses inhibition	Mus musculus
1.17.4.1	Hydroxyurea	2 mM, 93% inhibition, presence of 0.1 mM desferal potentiates inhibition	Mus musculus
1.17.4.1	additional information	inhibition of reductase by hydroxyurea, guanazole and pyrazolo-imidazole is potentiated by iron-chelating agents e.g. EDTA, desferrioxamine mesylate and 8-hydroxyquinoline, inhibition by 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone and 1-formylisoquinoline thiosemicarbazone is reversed by iron chelating agents	Mus musculus
1.17.4.1	Periodate-oxidized inosine	-	Mus musculus
1.17.4.1	pyrazoloimidazol	2 mM, 79% inhibition, presence of 0.1 mM desferal potentiates inhibition, inhibits the non-heme iron subunit	Mus musculus

Organism

EC Number	Organism	UniProt	Comment	Textmining
1.17.4.1	Mus musculus	-	Ehrlich ascites tumor cells	-

Source Tissue

EC Number	Source Tissue	Comment	Organism	Textmining
1.17.4.1	Ehrlich ascites carcinoma cell	-	Mus musculus	-

Substrates and Products (Substrate)

EC Number	Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
1.17.4.1	ribonucleoside diphosphate + reduced thioredoxin	-	Mus musculus	2'-deoxyribonucleoside diphosphate + oxidized thioredoxin + H2O	-	ir

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)